Know Cancer

forgot password

Wide-Field and High Resolution In Vivo Imaging of Oral Neoplasia Using Topical Fluorescent Dyes: A Feasibility Study

18 Years
Open (Enrolling)
Head and Neck Cancer

Thank you

Trial Information

Wide-Field and High Resolution In Vivo Imaging of Oral Neoplasia Using Topical Fluorescent Dyes: A Feasibility Study

Researchers are looking for new ways to look at mouth lesions using different light colors
and magnification. The devices in this study will be using different light colors that may
help doctors to decide if a mouth lesion has a high risk of being cancerous.

Two (2) different kinds of devices are being used in this study. One type is designed to let
researchers look at a wide area of the lining of the mouth (about the size of the top of a
soda can) by shining different colors of light into the mouth and taking pictures. The
devices used for this are the multi-spectral digital microscope (MDM), the Identafi 3000,
and the portable screening system (PS2 or PS2.1)

The second type of imaging device that will be used in this study is designed to let
researchers look at and take pictures of a very small area of the lining of the mouth, about
the size of a pencil tip, but at high magnification. This device is called the
High-Resolution Microendoscope (HRME).

Also, a coloring substance (a fluorescent dye which glows green in the dark) will be painted
on areas of the mouth with a cotton tip applicator to help improve the pictures.

Women who are able to become pregnant must have a negative blood (2 teaspoons) pregnancy
test to participate in this study. Women who are breast feeding or nursing will not be
eligible to participate in this study.

Mouth Exam:

If you agree to take part in this study, you will have a mouth exam. The study doctor will
take pictures of any lesions inside the mouth. The pictures will be taken under a standard
white light.

The study doctor will then take pictures of the inside of your mouth using one or more of
the first type of imaging devices (the MDM, the Identafi 3000, and/or the PS2) depending on
which device is available at that time. It should take about 1 minute to take all the
pictures. "Normal" (non-lesion) tissue in your mouth may also be imaged.

The pictures taken with the MDM and/or the Identafi 3000, and/or the PS2 will be studied to
better understand the use of different colors of light in mouth imaging.

A coloring substance (proflavine) will then be used to stain the mouth tissue, making it
easier for the HRME to take pictures. Using a cotton swab, the study doctor will brush up to
2 lesions and 1 normal (non-lesion) area in the mouth with proflavine. After up to 30
seconds, the study doctor will again look at and take pictures of the same mouth areas with
the MDM, and/or the Identafi 3000, and/or the PS2. Then a small probe (about the size of a
pencil tip) on the HRME will be placed against the lesions and the normal area inside your
mouth. Light from the end of the HRME probe will be used to take a picture of the stained
tissue. The HRME procedure should take less than 1-2 minutes at each tissue site. You will
then rinse your mouth with water or salt water after the procedures.

The mouth exam and any lesion imaging will all be done right before your scheduled surgery.
The imaging will be performed in the operating room right after you have gone to sleep but
before the start of your surgery. However, you may choose to have the imaging performed
while you are awake. The whole procedure should not take more than 10 to 15 minutes. It is
very unlikely that adding this amount of time under general anesthesia will cause you any
extra risk.

Biopsies and Tissue Removal:

After all imaging is complete, you will have tissue biopsies on any lesions that were
scanned, as well as the normal area that was scanned, to check if the tissue is cancerous or
pre-cancerous. These study biopsies will be performed during your already-scheduled surgery
while you are under general anesthesia (asleep). To collect a tissue biopsy, a small
cutting tool will be used to remove tissue from the lesions. Each sample will be about 4
millimeters wide (about the size of a pencil eraser). These samples will only be used for
the tests described here.

After the tissue biopsies are taken, the lesions will then be removed as part of your
scheduled surgery. The clinical results of the tested biopsy samples will be compared to
the pictures of the mouth tissue that were taken with the HRME and either the MDM and/or
Identafi 3000 and/or the PS2.

You will not be told of any of the experimental findings of this study. However, the results
will be available to your doctor.

All data (such as the tissue images and your diagnosis) will be coded with a number, instead
of your personal identifying information (such as your name or medical record number), to
help ensure your privacy.

Length of Study:

The imaging and tissue removal take around 10 to 15 minutes. After the tissue biopsies are
complete, your active participation in the study will be over. Researchers may contact you
during your routine follow-up visits to see how you are doing and to check if you have had
any problems from the imaging procedures. You may also be contacted by telephone or e-mail
by research personnel for up to one year.

This is an investigational study. The HRME, PS2, and MDM devices are not FDA approved or
commercially available. Their use in this study is investigational. The Identafi 3000 is FDA
approved and commercially available. Proflavine is not FDA approved or commercially
available for use as a dye in the mouth. Its use in this study is investigational.

Up to 155 patients will take part in this study. All will be enrolled at MD Anderson.

Inclusion Criteria:

1. Adult subjects with oral lesions undergoing surgical resection (i.e., only patients
who are scheduled to undergo a surgery of the Head & Neck area to remove or biopsy
oral lesions will be eligible to participate in the study). Patients with previous
treatment are eligible.

2. Ability to understand and the willingness to sign a written Informed Consent Document

Exclusion Criteria:

1. Known allergy to proflavine or acriflavine.

2. Age less than 18 years.

3. Pregnant or nursing females.

4. The participant will be excluded from participation in another clinical research
trial (i.e., a trial in which an agent is actively administered to the study
subject), while being imaged (on active treatment) on this protocol.

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Feasibility Assessing Oral Mucosa In Vivo with Wide-field and High resolution Images using New Optical and Topically Contrast Agent

Outcome Description:

Assessments: 1) Standard white light headlamp where clinical impression classified into "normal", "abnormal low risk", "abnormal high risk", or "cancer"; 2) Widefield multispectral imaging digital images before topical fluorescent dyes, and 3) digital images by a widefield multispectral imaging device &/or high-resolution optical system after topical dyes where images reviewed by investigators blinded to clinical impression and histopathology diagnosis, classify lesions as "suspicious" or "not suspicious"; and, 4) Histopathology based on biopsy samples used as gold standard.

Outcome Time Frame:

3 years for patient enrollment; patient participation 10 - 15 minute imaging and tissue biopsy procedure prior to surgery for removal of lesion

Safety Issue:


Principal Investigator

Ann M. Gillenwater, MD, BA

Investigator Role:

Study Chair

Investigator Affiliation:

UT MD Anderson Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

December 2010

Completion Date:

Related Keywords:

  • Head and Neck Cancer
  • oral mucosa in vivo
  • Wide-Field In Vivo Imaging
  • High Resolution In Vivo Imaging
  • Oral Neoplasia
  • Topical Fluorescent Dyes
  • contrast dye
  • oral dysplasia
  • Proflavine
  • oral lesions
  • surgical resection
  • High Resolution Microendoscope
  • HRME
  • Identafi 3000
  • Multispectral Digital Microscope
  • MDM
  • Portable Screening System
  • PS2
  • Neoplasms
  • Head and Neck Neoplasms



UT MD Anderson Cancer CenterHouston, Texas  77030